sinemet cr
organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.
epinosine b forte injection
wael pharmacy - disodium adenosine triphosphate trihydrate, nicotinamide - injection
inbrija
acorda therapeutics ireland limited - levodopa - parkinson disease - anti-parkinson drugs - inbrija is indicated for the intermittent treatment of episodic motor fluctuations (off episodes) in adult patients with parkinson’s disease (pd) treated with a levodopa/dopa-decarboxylase inhibitor.
stalevo 5012.5200 mg
inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.
stalevo 15037.5200 mg
inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.
ongentys
bial - portela cª, s.a. - opicapone - parkinson disease - anti-parkinson drugs - ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
ontilyv
bial portela & companhia s.a. - opicapone - parkinson disease - anti-parkinson drugs - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - amino acid metabolism, inborn errors - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.1).
carbidopa/levodopa orion 12.5 mg/50 mg tablets
orion corporation - carbidopa monohydrate; levodopa - tablet - levodopa and decarboxylase inhibitor
carbidopa/levodopa orion 25 mg/100 mg tablets
orion corporation - carbidopa monohydrate; levodopa - tablet - levodopa and decarboxylase inhibitor